Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

H. Hjorth-Hansen, J. Stentoft, J. Richter, P. Koskenvesa, M. Höglund, A. Dreimane, K. Porkka, T. Gedde-Dahl, B. T. Gjertsen, F. X. Gruber, L. Stenke, K. M. Eriksson, B. Markevärn, A. Lübking, H. Vestergaard, L. Udby, O. W. Bjerrum, I. Persson, S. Mustjoki, U. Olsson-Strömberg

Research output: Contribution to journalArticlepeer-review

44 Citations (SciVal)

Abstract

Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 μg/week and it increased to 25 μg/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR 4 was achieved by 46% and MR 4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS±PegIFN is warranted.

Original languageEnglish
Pages (from-to)1853-1860
Number of pages8
JournalLeukemia
Volume30
Issue number9
DOIs
Publication statusPublished - 2016 Sep 1
Externally publishedYes

Subject classification (UKÄ)

  • Hematology
  • Cancer and Oncology

Fingerprint

Dive into the research topics of 'Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients'. Together they form a unique fingerprint.

Cite this